Founded in 1996, Kelun has now formed a "Pin"-shaped architecture operation platform composed of Kelun Pharmaceutical, Chuanning Biotechnology and Kelun Botai, with a total market value of over 100 billion yuan. In 2018, Kelun was named "Manufacturing Single Champion Demonstration Enterprise" for his global advantages in large-capacity injections.

Sichuan Kelun Pharmaceutical Co., Ltd. was successfully listed on the Shenzhen Stock Exchange in June 2010, and immediately launched the 10 billion industry investment plan and began to implement the development strategy of "three-in-one developments, innovative growth". The first engine maintains Kelun's leading position in the infusion field through continuous industrial upgrading and variety structure adjustment; the second engine builds from intermediates, raw materials to preparations through innovative development and utilization of high-quality natural resources. The third engine accumulates the ultimate driving force for the everlasting enterprise foundation through the construction of the R&D system and diversified technological innovation.

In the field of infusion, Kelun has achieved comprehensive industrial upgrading, and has the profitability of both high-end manufacturing and new materials, occupying a strategic high ground for technological innovation and quality benchmarks. Columbia has established a closed responsibility system from drug research and development, production and manufacturing, logistics and transportation to terminal use to ensure product quality and safety. The leading products have been exported in batches and enjoy a high reputation in more than 50 countries and regions. The stand-up bag® independently developed by Kelun is the first at home and abroad. It has more than 20 patents and has won the National Science and Technology Progress Award. It has higher safety and cost-effectiveness than traditional infusions, and has great application value in reducing energy consumption and environmental protection, representing the direction of development of Chinese infusion products.

In the field of antibiotics, the company has established Yili Chuanning Biotechnology Co., Ltd. to produce erythromycin thiocyanate and cephalosporin series intermediates. Through R&D testing, upgrading and optimization, innovative cooperation, and the introduction of advanced domestic and foreign technology equipment, Sichuan Ning has been approved to build a National Environmental Protection Antibiotic Bacterial Slag Harmless Treatment and Resource Utilization Engineering Technology Center, solving the source problems of the antibiotic industry. In December 2022, Chuanning Biotech was successfully listed on the Shenzhen Stock Exchange GEM and entered the field of synthetic biology.

Kelun has applied for more than 1,300 invention patents and obtained more than 700 invention patents. He has launched the development of more than 500 major drugs in many diseases such as tumors, bacterial infections, parenteral nutrition, etc.; since 2017, it has been approved for marketing every year. More than 20 items have become the leading generic drug enterprise in China, and has become the leading supplier of national centralized drug procurement with a winning rate of nearly 90%. At the same time, more than ten innovations are used to treat major diseases such as tumors, autoimmunity, inflammation, and metabolism. The drug project is in its clinical stage, with multiple clinical trials being a global multi-center research. Multiple projects work together with European and American partners to deploy global clinical research and are carried out simultaneously in multiple countries including China and Europe and the United States to achieve the synergy of pipelines and technology platforms. Effects, maximize the global value of pipelines.